Last Close
Apr 08  •  10:52AM ET
1.42
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-31.01 Insider Own8.57% Shs Outstand3.60M Perf Week-23.66%
Market Cap5.12M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.29M Perf Month-34.86%
Enterprise Value-5.52M PEG- EPS next Q- Inst Own5.16% Short Float1.73% Perf Quarter-75.09%
Income-46.90M P/S12.19 EPS this Y- Inst Trans-5.12% Short Ratio0.05 Perf Half Y-87.54%
Sales0.42M P/B0.14 EPS next Y- ROA-95.40% Short Interest0.06M Perf YTD-71.93%
Book/sh9.85 P/C0.43 EPS next 5Y- ROE-125.15% 52W High46.50 -96.95% Perf Year-84.19%
Cash/sh3.29 P/FCF- EPS past 3/5Y-37.47% - ROIC-221.18% 52W Low1.36 4.41% Perf 3Y-96.78%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-76.97% -64.54% Gross Margin-217.83% Volatility10.31% 20.64% Perf 5Y-99.49%
Dividend TTM- EV/Sales-13.14 EPS Y/Y TTM15.01% Oper. Margin-7529.23% ATR (14)0.34 Perf 10Y-
Dividend Ex-Date- Quick Ratio3.59 Sales Y/Y TTM-45.69% Profit Margin-11213.62% RSI (14)35.71 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio3.87 EPS Q/Q-22.74% SMA20-33.01% Beta1.45 Target Price45.00
Payout- Debt/Eq0.06 Sales Q/Q-60.06% SMA50-38.77% Rel Volume0.14 Prev Close1.42
Employees115 LT Debt/Eq0.03 EarningsMar 31 AMC SMA200-81.36% Avg Volume1.21M Price1.42
IPOJul 12, 2017 Option/ShortNo / Yes EPS/Sales Surpr.-354.17% 108.50% Trades Volume41,803 Change0.00%
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.